Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2033. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2033
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2018 to 2039.
US 10,772,911
Cell Free Compositions for Cellular Restoration and Methods of Making and Using Same
Dec 19, 2034
US 11,219,643
Compositions for Cellular Restoration and Methods of Making and Using Same
Jul 16, 2035
202220262030203420382039
1 pending application: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2034 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Apr 2034 · High confidence
Also notable
Ends Apr 2037 · High confidence
Also notable
Ends Jan 2039 · High confidence
Cell Free Compositions for Cellular Restoration and Methods of Making and Using Same
US 10,772,911
The most cited patent in this portfolio, cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2034.
Reprogramming of Aged Adult Stem Cells
US 11,286,463
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2033.
Compositions for Cellular Restoration and Methods of Making and Using Same
US 9,994,814
The most cited patent in this portfolio, cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2034.
Microrna Compositions and Methods of Making and Using Same
US 11,203,754
Granted 2021. Computed term ends 2037.
Therapeutic Compositions and Methods of Making and Using the Same
US 10,717,981
Granted 2020. Computed term ends 2039.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 3 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Cell Free Compositions for Cellular Restoration and Methods of Making and Using Same | 2 in force | to Jul 2035 |
| Compositions for Cellular Restoration and Methods of Making and Using Same | 1 in force | to Apr 2034 |
| Reprogramming of Aged Adult Stem Cells | 1 in force | to Mar 2033 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,286,463 | Reprogramming of Aged Adult Stem Cells In force · High confidence | In force | High confidence | |
| US 9,994,814 | Compositions for Cellular Restoration and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 10,772,911 | Cell Free Compositions for Cellular Restoration and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 11,219,643 | Compositions for Cellular Restoration and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 11,203,754 | Microrna Compositions and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 10,717,981 | Therapeutic Compositions and Methods of Making and Using the Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 1 application pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.